Polymyxin B hemoperfusion and mortality in abdominal septic shock [3]

JAMA

Volumn 302, Issue 18, 2009, Pages 1968-1969

  Amaral, Andre C K B ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN B; ANTIINFECTIVE AGENT;

DRUG EFFICACY; HEMOPERFUSION; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; NOTE;

ANTI-BACTERIAL AGENTS; HEMOPERFUSION; HUMANS; POLYMYXIN B; SHOCK, SEPTIC;

EID: 70450042816     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1607     Document Type: Letter

References (5)

1. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445-2452.
2. Schoenfeld D. Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies. Crit Care. 2006;10(1):103. (Pubitemid 47079842)
3. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective- ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338(6):347-354. (Pubitemid 28083906)
4. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [published correction in JAMA. 2008;300(14):1652]. JAMA. 2002;288(7):862-871.
5. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323(7321):1123-1124.